UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Leukemia, 2020-08, Vol.34 (8), p.2125-2137

2020

Volltextzugriff (PDF)

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

Blood, 2000-08, Vol.96 (4), p.1525-1530

2000

Volltextzugriff (PDF)

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Leukemia, 2008-09, Vol.22 (9), p.1707-1711

2008

Volltextzugriff (PDF)

Phase 1 study of PTK787 ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

Leukemia, 2006-06, Vol.20 (6), p.952-957

2006

Volltextzugriff (PDF)

In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche

Leukemia, 2016-07, Vol.30 (7), p.1582-1586

2016

Volltextzugriff (PDF)

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

The New England journal of medicine, 2018-06, Vol.378 (25), p.2386-2398

2018

Volltextzugriff (PDF)

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

The New England journal of medicine, 2020-12, Vol.383 (26), p.2526-2537

2020

Volltextzugriff (PDF)

P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG‐TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML‐001 TRIAL OF ORAL AZACITIDINE

HemaSphere, 2022-06, Vol.6, p.397-398

2022

Volltextzugriff (PDF)

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

HemaSphere, 2022-06, Vol.6, p.660-661

2022

Volltextzugriff (PDF)

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia

Leukemia & lymphoma, 2002-10, Vol.43 (10), p.1951-1955

2002

Volltextzugriff (PDF)

Epidermal Growth Factor and Basic Fibroblast Growth Factor Have Independent Actions on Mesencephalic Dopamine Neurons in Culture

Journal of neurochemistry, 1994-06, Vol.62 (6), p.2166-2177

1994

Volltextzugriff (PDF)

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Haematologica (Roma), 2016-06, Vol.101 (6), p.e224

2016

Volltextzugriff (PDF)

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Haematologica (Roma), 2015-02, Vol.100 (2), p.231

2015

Volltextzugriff (PDF)

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4110-4116

2005

Volltextzugriff (PDF)

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

Blood, 2000-08, Vol.96 (4), p.1525-1530

2000

Volltextzugriff (PDF)

Hepatitis C and B-cell lymphoma

AIDS patient care and STDs, 1998-08, Vol.12 (8), p.605-609

Roboz, G J

1998

Volltextzugriff (PDF)

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6526-6526

2010

Volltextzugriff (PDF)

Interleukin-5 and the regulation of eosinophil production

Current opinion in hematology, 1999-05, Vol.6 (3), p.164-164

1999

Volltextzugriff (PDF)

A humanized unconjugated antibody targeting CD33 (SGN-33; huM195) is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.16500-16500

2006

Volltextzugriff (PDF)

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2025-2025

2006

Volltextzugriff (PDF)

HIV/AIDS case histories: diagnostic problems. Hodgkin's disease, mixed cellularity type

AIDS patient care and STDs, 1999-01, Vol.13 (1), p.57-58

1999

Volltextzugriff (PDF)

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Leukemia research, 2003-12, Vol.27 (12), p.1091-1096

2003

Volltextzugriff (PDF)

HIV/AIDS Case Histories: Diagnostic Problems

AIDS patient care and STDs, 1999-01, Vol.13 (1), p.57-58

1999

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(133)

Publikationsform

Artikel
(156)

Sprache

Englisch
(155)
Japanisch
(9)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(31)
Journal Of Clinical Oncology
(13)
Leukemia Research
(11)
Leukemia
(9)
Annals Of The New York Academy Of Sciences
(5)
Cancer Research
(4)
Hemasphere
(4)
Leukemia & Lymphoma
(4)
Aids Patient Care And Stds
(3)
Annals Of Oncology
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

Phase 1 study of PTK787 ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG‐TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML‐001 TRIAL OF ORAL AZACITIDINE

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia

Epidermal Growth Factor and Basic Fibroblast Growth Factor Have Independent Actions on Mesencephalic Dopamine Neurons in Culture

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

Hepatitis C and B-cell lymphoma

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Interleukin-5 and the regulation of eosinophil production

A humanized unconjugated antibody targeting CD33 (SGN-33; huM195) is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function

HIV/AIDS case histories: diagnostic problems. Hodgkin's disease, mixed cellularity type

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

HIV/AIDS Case Histories: Diagnostic Problems

Suchergebnisse filtern